Curis, Inc. (CRIS) Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update
11/6/2013 9:24:13 AM
LEXINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop novel, targeted drug candidates for the treatment of human cancers, today provided an update on the Phase 1 clinical trial of its oral inhibitor of apoptosis (IAP) antagonist, CUDC-427 and reported its financial results for the third quarter ended September 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by